These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34646659)

  • 1. Continuous Effectiveness of Pneumococcal 13-Valent Conjugate Vaccine on Pediatric Pneumococcal Otomastoiditis: Results of 15 Years of Active/Prospective Surveillance in a Mexican Hospital on the Mexico-US Border.
    Chacon-Cruz E; Lopatynsky EZ
    Cureus; 2021 Aug; 13(8):e17608. PubMed ID: 34646659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of the 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-Serotype Otitis Media.
    Dagan R; Van Der Beek BA; Ben-Shimol S; Pilishvili T; Givon-Lavi N
    Clin Infect Dis; 2021 Aug; 73(4):650-658. PubMed ID: 33507250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV.
    Ben-Shimol S; Givon-Lavi N; Leibovitz E; Raiz S; Greenberg D; Dagan R
    Clin Infect Dis; 2014 Dec; 59(12):1724-32. PubMed ID: 25159581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. General health, otitis media, nasopharyngeal carriage and middle ear microbiology in Northern Territory Aboriginal children vaccinated during consecutive periods of 10-valent or 13-valent pneumococcal conjugate vaccines.
    Leach AJ; Wigger C; Beissbarth J; Woltring D; Andrews R; Chatfield MD; Smith-Vaughan H; Morris PS
    Int J Pediatr Otorhinolaryngol; 2016 Jul; 86():224-32. PubMed ID: 27260611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric meningitis due to
    Chacon-Cruz E; Roberts C; Rivas-Landeros RM; Lopatynsky-Reyes EZ; Almada-Salazar LA; Alvelais-Palacios JA
    Ther Adv Infect Dis; 2019; 6():2049936119832274. PubMed ID: 30886712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
    Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 12 years active surveillance for pediatric pleural empyema in a Mexican hospital: effectiveness of pneumococcal 13-valent conjugate vaccine, and early emergence of methicillin-resistant
    Chacon-Cruz E; Rivas-Landeros RM; Volker-Soberanes ML; Lopatynsky-Reyes EZ; Becka C; Alvelais-Palacios JA
    Ther Adv Infect Dis; 2019; 6():2049936119839312. PubMed ID: 30984396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Streptococcus pneumoniae Serotypes Identified in Mexican Children with Invasive Disease Before and After the Introduction of PCV7 (1993-2012).
    Echaniz-Aviles G; Soto-Nogueron A; Miranda-Novales G; Carnalla-Barajas MN; Velazquez-Meza ME; Solórzano-Santos F;
    Arch Med Res; 2015 Feb; 46(2):149-53. PubMed ID: 25743930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of 13-valent pneumococcal conjugate vaccination for protection against acute otitis media caused by Streptococcus pneumoniae in healthy young children: a prospective observational study.
    Pichichero M; Kaur R; Scott DA; Gruber WC; Trammel J; Almudevar A; Center KJ
    Lancet Child Adolesc Health; 2018 Aug; 2(8):561-568. PubMed ID: 30119715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study.
    Cohen C; von Mollendorf C; de Gouveia L; Lengana S; Meiring S; Quan V; Nguweneza A; Moore DP; Reubenson G; Moshe M; Madhi SA; Eley B; Hallbauer U; Finlayson H; Varughese S; O'Brien KL; Zell ER; Klugman KP; Whitney CG; von Gottberg A;
    Lancet Glob Health; 2017 Mar; 5(3):e359-e369. PubMed ID: 28139443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Widespread Introduction of Pneumococcal Conjugate Vaccines on Pneumococcal and Nonpneumococcal Otitis Media.
    Ben-Shimol S; Givon-Lavi N; Leibovitz E; Raiz S; Greenberg D; Dagan R
    Clin Infect Dis; 2016 Sep; 63(5):611-8. PubMed ID: 27225239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter surveillance of Streptococcus pneumoniae isolates from middle ear and mastoid cultures in the 13-valent pneumococcal conjugate vaccine era.
    Kaplan SL; Center KJ; Barson WJ; Ling-Lin P; Romero JR; Bradley JS; Tan TQ; Hoffman JA; Peters TR; Gurtman A; Scott DA; Trammel J; Gruber WC; Hulten KG; Mason EO
    Clin Infect Dis; 2015 May; 60(9):1339-45. PubMed ID: 25648240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substantial reduction of antibiotic-non-susceptible pneumococcal otitis media following PCV7/PCV13 sequential introduction.
    Ben-Shimol S; Givon-Lavi N; Greenberg D; van der Beek BA; Leibovitz E; Dagan R
    J Antimicrob Chemother; 2020 Oct; 75(10):3038-3045. PubMed ID: 32946586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National impact of 13-valent pneumococcal conjugate vaccine on ambulatory care visits for otitis media in children under 5 years in the United States.
    Zhou X; de Luise C; Gaffney M; Burt CW; Scott DA; Gatto N; Center KJ
    Int J Pediatr Otorhinolaryngol; 2019 Apr; 119():96-102. PubMed ID: 30690309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in Otitis Media Episodes and Pressure Equalization Tube Insertions Among Young Children Following Introduction of the 13-Valent Pneumococcal Conjugate Vaccine: A Birth Cohort-based Study.
    Wiese AD; Huang X; Yu C; Mitchel EF; Kyaw MH; Griffin MR; Grijalva CG
    Clin Infect Dis; 2019 Nov; 69(12):2162-2169. PubMed ID: 30770533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging Streptococcus pneumoniae Strains Colonizing the Nasopharynx in Children After 13-valent Pneumococcal Conjugate Vaccination in Comparison to the 7-valent Era, 2006-2015.
    Kaur R; Casey JR; Pichichero ME
    Pediatr Infect Dis J; 2016 Aug; 35(8):901-6. PubMed ID: 27420806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
    Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
    Gidding HF; McCallum L; Fathima P; Moore HC; Snelling TL; Blyth CC; Jayasinghe S; Giele C; de Klerk N; Andrews RM; McIntyre PB;
    Vaccine; 2018 May; 36(19):2650-2656. PubMed ID: 29627233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.